Inflect Capital

The world has hard problems to solve, and answers are urgently needed. We help entrepreneurs on a mission to solve these hard problems build companies. We believe Singapore has the resources and capabilities to tackle the pressing challenges impacting people around the world. SGInnovate has been established to help these ambitious and capable people to build 'technology-intensive' products borne out of scientific research, leveraging the full power of the Singapore ecosystem to achieve this mission. Investment Capital Singapore has over $1b+ of private-market funds and another $1b+ of public-sector funds. Government Singapore remains one of the most attractive and trusted places to build companies, in large part due to our economic competitiveness, as well as political and operational stability. Research A global research and innovation hub, S$25B has been committed to Singapore's latest Research, Innovation and Enterprise (RIE) five-year plan, covering domains such as healthcare, sustainability and manufacturing, through to 2025. Corporate Backing Singapore brings together over 7000 regional and global corporations who represent go-to-market help, joint product development, investment funding and possible exits. World Class Institute of Higher Learning Singapore is home to two of the top 20 globally-ranked universities.

We’re making healthcare massively better by investing in the next generation of entrepreneurs, advising major corporations on what matters in digital health, and working to scale health equity for all humanity. Rock Health Capital makes healthcare massively better for every human being by investing in remarkable entrepreneurs working at the intersection of healthcare and technology.

We believe that the future of modern healthcare is led by a digital revolution. Investing in solutions that help to transforms these challenges healthcare is facing. When technology is fuelled by digitalisation, innovation will thrive and grow, creating leverage for global reform. By supporting innovative digital-health startups with seed capital, extensive industry knowledge and a powerful global network, we aim to change the future of healthcare forever. Entrepreneurial capital: Our work is rooted in a deep understanding of the system in which we operate. Pioneering: We believe that the future of modern healthcare is led by a digital revolution. Committed to impact: There is an idealistic element to our proposition. The aim of our efforts is change. Human centred: People are at the core of everything we do. They are the end to our means and the why to our what. From a business perspective this translates into a strong desire to invest in a team, rather than a business plan. We believe in long term shared success. The Approach In return for the invested capital and support, Healthy.Capital acquires a minority share. We are: Team with experts Entrepreneurs by heart Specialist in building product-market fit Long term investment relationships Digital Health VC with international network Ecosystem key player Our initially invested capital ranges between EUR 200K and EUR 1 M. Once a board, and depending on the proposition, we will offer support with a startup mentality in the following areas: Strategy Building Coaching Operational Expertise Business Development Health & Care Expertise Co-investments Financial Roadmap Planning Network Expansion Healthy.Capital invests in talented founders & teams. Our focus is Digital Health Solutions Services SaaS Marketplaces Our Criteria Business entity registered in the Netherlands Company younger than 7 years old Tech component (pre-)Seed stage Excellent teams Data driven DNA Strong problem-solution fit High scalability with healthy profitability

We're looking for the rebels. We invest in the underdogs. The contrarians. The resilient. We want to write the untold stories that rewire prevailing ways of thinking and doing. We’re a VC firm that helps build, not bet on, companies transforming massive industries. We started from an MIT dorm room during the Great Recession and spent the last decade helping build industry-leading companies, often bringing them their biggest, million-dollar customers. Everyone told us we were crazy when we got started. Now we have offices in Boston, San Francisco, and London. We like defying the crowd, following our instincts, and proving them wrong. We love if you do too. We admire people who think really big. Those who want to craft legendary, contrarian companies worth $5B or more. Those who have an irrational belief in your vision. We are very patient and have both youth and experience on our side, and we are hungry to build. We lead Seed, Series A, and early Series B rounds. We prefer B2B companies tackling large traditional industries and/or commercializing research from top-tier groups. We are generalist, but themes that excite us include: human-machine convergence (augmentation and automation) consumer-enterprise interface (digitalization of the consumer experience) enterprise agility (‘real-time’ actionable insights from novel data sources) new industrial revolution (use of sensors and software in industry) security of all data (more digitalization, more security problems) software eating healthcare (making delivery more accurate, efficient, efficacious) generation Z (the future) How much are you looking to raise?$0 - 3M (Pre-Seed / Seed): We write small checks into multiple companies at the Seed stage. Our goal is to work closely with you to determine whether we should continue our investment at the Series A. Historically, we have achieved a 2:1 ratio in terms of Seed investments to Series A follow-on rounds. $3 - 10M (Series A): We lead $3-10M rounds at the Series A stage. Our core investments are either follow-on investments from companies we’ve seeded or first checks into new additions to our portfolio. As the lead institutional investor in your company, we will work closely with your executive team and board and serve as a true partner in your growth. $10 - 20M (Series B): We lead $10-20M rounds at the Series B stage. A portion of these investments will be follow-ons from our Series A companies, but many will be new additions to our portfolio. We partner with entrepreneurs who are uninterested in raising artificially inflated rounds and who seek active partners to help hire executives, build boards, and optimize growth strategy. How we help We don’t bet. We build – and that starts from our first interaction with each entrepreneur. We work tirelessly to add value to the companies in our portfolio, and we base that strategy around four core pillars. Customer Acquisition: We help you kick down doors, secure early pilots, and win contracts with key customers. Building Go-to-Market Teams: We work closely with you to find and win the best talent for your most critical roles. Fundraising Strategies: We guide you as you prepare and pursue additional capital to build and grow. Board-Level Strategy: We support you in making decisions as an experienced voice at the table, and we bring in other players who can add outsized value.

We are inspired by a vision for the future in which data, computing, networks, and other digital and deep technologies deliver meaningful outcomes and insight for improving health and the provision of care. We invest in both solutions intended for use in the diagnosis or cure of disease and solutions designed to help healthcare organizations - be them hospitals, biopharmas, insurers, etc. - be better at what they do. We see our sweet spot at seeding founders who are marrying in-depth understanding of the complex network of healthcare system participants with meaningful engineering innovation, advanced data science, and information technology-enabled products and services. We look for and invest in founders determined to effectively and efficiently serve these participants on the european continent, where we are based, and internationally.​ In our investment criteria and process, we are informed by a Stanford-born methodology of health technology innovation known as Biodesign. Since 2001, Biodesign has proven to de-risk the process of new venture creation by applying a need-driven and value-based approach to reinventing healthcare with the help of technology. To learn more about the methodology, head to The Student Guide to Biodesign, developed by a team of Stanford instructors and students who are passionate about education and making high-quality learning materials available and accessible to all.​ We invest in european companies as well as in selected non-european companies with ties to europe. Wherever they are, our goal is to help founders ready their companies to raise series A capital, and to access international markets. To learn more about our process, click here.

Rubicon seeks to both invest and partner to build meaningful businesses that create enduring value by transforming the way people receive healthcare. Rubicon’s approach to investing is guided by a deliberative analytic process building ground-up businesses from scratch, as well as empowering large platform and special opportunity companies. GROUND UPWe partner to create transformational companies because we believe there are better ways to solve today’s healthcare challenges. Our ground up business concepts apply data-driven processes to identify value edge, a form of competitive advantage, and combine with mission driven teams. PLATFORM & SPECIAL OPPORTUNITIESWe partner with exceptional companies that create value by transforming lives. We focus on unique healthcare assets that pioneer healthcare solutions.